Actuate Therapeutics, Inc. (ACTU)

Market Cap	69.59M -60.2%
Revenue (ttm)	n/a
Net Income	-22.23M
EPS	-1.06
Shares Out	23.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,029
Open	2.860
Previous Close	2.975
Day's Range	2.850 - 3.085
52-Week Range	1.580 - 11.990
Beta	n/a
Analysts	Strong Buy
Price Target	17.50 (+496.25%)
Earnings Date	May 14, 2026

About ACTU

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apothe...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 13, 2024
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: ACTU
• Website: https://actuatetherapeutics.com

Analyst Summary

According to 2 analysts, the average rating for ACTU stock is "Strong Buy." The 12-month stock price target is $17.5, which is an increase of 496.25% from the latest price.

Price Target

$17.5

(496.25% upside)

Analyst Consensus: Strong Buy